61718-82-9COCCCC/C(=N/OCCN)c1ccc(C(F)(F)F)cc1.O=C(O)/C=C\C(=O)OLFMYNZPAVPMEGP-SHNAKOFWSA-N61718-82-9Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
1-Pentanone, 5-methoxy-1-4-(trifluoromethyl)phenyl-, O-(2-aminoethyl)oxime, (1E)-, (2Z)-2-butenedioate (1:1): Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
BeschreibungFluvoxamine maleate is the most recent of the serotonin-specific antidepressants to reach the market. In vitro and in vivo animal experiments have shown fluvoxamine to have a marked effect on 5-HT mediated processes and little effect on norepinephrine. Clinical trials suggest similar efficacy to imipramine and clomipramine with a somewhat lower incidence of side effects, especially anticholinergic effects. Fluvoxamine, in contrast to the tricyclic antidepressants, does not appear to produce heart rate increase, postural hypotension or prolongation of the intraventricular conduction time and QT interval.
VerwendenFluvoxamine maleate has been used as a test compound to determine the solubility and effective blood-brain barrier permeability.(2)
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…